Mostrar el registro sencillo del ítem

dc.contributor.authorGómez Caamaño, Antonio 
dc.contributor.authorGonzález-San Segundo, C.
dc.contributor.authorHenríquez, I.
dc.contributor.authorMaldonado, X.
dc.contributor.authorZapatero, A.
dc.date.accessioned2021-10-07T08:56:31Z
dc.date.available2021-10-07T08:56:31Z
dc.date.issued2019
dc.identifier.issn1699-048X
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/30293231es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/15469
dc.description.abstractBACKGROUND: The knowledge in the field of castration-resistant prostate cancer (CRPC) is developing rapidly, with emerging new therapies and advances in imaging. Nonetheless, in multiple areas there is still a lack of or very limited evidence, and clear guidance from clinicians regarding optimal strategy is required. METHODS: A modified Delphi method, with 116 relevant questions divided into 7 different CRPC management topics, was used to develop a consensus statement by the URONCOR group. RESULTS: A strong consensus or unanimity was reached on 93% of the proposed questions. The seven topics addressed were: CRPC definition, symptomatic patients, diagnosis of metastasis, CRPC progression, M0 management, M1 management and sequencing therapy, and treatment monitoring. CONCLUSIONS: The recommendations based on the radiation oncology experts' opinions are intended to provide cancer specialists with expert guidance and to standardise CRPC patient management in Spain, facilitating decision-making in different clinically relevant issues regarding CRPC patients.en
dc.language.isoeng
dc.rightsAtribución 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleConsensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncologyes
dc.typeArtigoes
dc.authorsophosGómez-Caamaño, A.
dc.authorsophosGonzález-San Segundo, C.
dc.authorsophosHenríquez, I.
dc.authorsophosMaldonado, X.
dc.authorsophosZapatero, A.
dc.identifier.doi10.1007/s12094-018-1940-2
dc.identifier.pmid30293231
dc.identifier.sophos30779
dc.issue.number4es
dc.journal.titleClinical & Translational Oncologyes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Oncoloxía Radioterápica
dc.page.initial420es
dc.page.final432es
dc.relation.publisherversionhttps://link.springer.com/content/pdf/10.1007/s12094-018-1940-2.pdf
dc.rights.accessRightsopenAccess
dc.subject.keywordCHUS
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)
dc.typesophosArtículo Original
dc.volume.number21es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional